No products in the cart.
$130.00
Retatrutide is a triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously — a more comprehensive mechanism than semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual). Developed by Eli Lilly, retatrutide has shown remarkable results in Phase 2 clinical trials, with participants achieving average weight loss of 24.2% of body weight at 48 weeks — among the highest figures recorded for any pharmaceutical intervention short of bariatric surgery. X-Fuel Retatrutide is supplied at 10mg per vial, ultra-purity research grade. This is the compound the advanced community has been watching closely since the 2023 trial data dropped.
Retatrutide 10mg — Ultra-Purity Research Grade
What Is Retatrutide?
Retatrutide (LY3437943) is a once-weekly injectable peptide developed by Eli Lilly that simultaneously activates three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple agonism distinguishes it from semaglutide (Ozempic/Wegovy — GLP-1 only) and tirzepatide (Mounjaro/Zepbound — GLP-1/GIP dual agonist).
The addition of glucagon receptor agonism to the GLP-1/GIP combination is theorised to further enhance lipolysis (fat breakdown) and energy expenditure, potentially explaining retatrutide’s superior weight loss outcomes in early trials.
X-Fuel Retatrutide is supplied at 10mg per vial, lyophilised to ultra-purity research grade.
The Clinical Trial Data
The Phase 2 TRIUMPH-1 trial (published in NEJM, 2023) is the reason the community is paying attention. Key findings:
These numbers compare to approximately 15% for semaglutide and 22% for tirzepatide — placing retatrutide at the leading edge of pharmacological weight management as of 2024.
Why the Community Uses It
Retatrutide has attracted interest from several distinct communities:
Advanced GLP-1 Stack Users
Those who have used semaglutide and tirzepatide and are looking for the next step. Retatrutide represents the more aggressive option in the GLP-1/GIP/glucagon triple-agonist class.
Body Composition Athletes
Competitive physique athletes using GLP-1 class compounds for contest prep, off-season body fat management, and insulin sensitivity. The glucagon receptor component adds a lipolysis dimension not present in semaglutide.
Metabolic Optimisation
Beyond weight loss, the trial data showed improvements in multiple cardiometabolic markers — making retatrutide relevant to those managing metabolic syndrome parameters.
Mechanism of Action
GLP-1 receptor agonism: Slows gastric emptying, promotes satiety, reduces food intake, and stimulates glucose-dependent insulin secretion.
GIP receptor agonism: Enhances insulin secretion in response to glucose, may improve insulin sensitivity, and has been associated with reduced GLP-1 side effects (nausea).
Glucagon receptor agonism: Increases hepatic glucose output and promotes lipolysis — adding an energy expenditure/fat-burning dimension to the mechanism.
Reconstitution & Storage
Supplied lyophilised. Reconstitute with bacteriostatic water. Store unreconstituted at 2–8°C. Reconstituted solution should be refrigerated and used within 28 days. Protect from light at all stages. Retatrutide, like all GLP-1 class peptides, is designed for subcutaneous injection.
Storage Information
Refrigerate lyophilised vial at 2–8°C. Once reconstituted with bacteriostatic water, refrigerate and use within 28 days. Protect from light. Do not freeze reconstituted solution.
Usage & Reconstitution
Reconstitute with bacteriostatic water. Subcutaneous injection — typically abdomen, thigh, or upper arm. Retatrutide follows a dose titration protocol similar to other GLP-1 class peptides — starting at low doses and escalating slowly to mitigate GI side effects (nausea, vomiting).
The team at X-Fuel is here to answer any question you may have for all of our products. Send us a message today!
X-Fuel is a leading provider of Canadian Steroids and ships within Canada nationwide with discreet and fast shipping.
Email: [email protected]
Address: 800 Yates St
Victoria, British Columbia, Canada V8W 1L8
